

CHARTTRENDS®: NEPHROLOGY IN CHINA

ChartTrends®: Nephrology in China is a syndicated report that captures patient level data from 1000 unique late stage (Stage 3 / Stage 4 / Stage 5 not on dialysis) Chronic Kidney Disease (CKD) patient records and 1000 unique dialysis patient records. ChartTrends® are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as patient co-morbidities, use of various treatments, product dosing, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

SAMPLE FRAME AND METHODOLOGY

200+ Nephrologists submit 1000 CKD-ND Patient Chart Records and 1000 dialysis Patient Chart Records

Nephrologist Screening Criteria:

- In practice between 2 and 30 years
- Minimum of 100 adult CKD Stage 3, 4, 5 (not on dialysis) patients and 50 dialysis patients under management
- Tier 3 hospital-based, urban setting

Patient Criteria:

- At least 18 years of age
- CKD Stage 3, 4, or 5 not on dialysis / Dialysis

All methods are compliant with patient privacy laws

PRODUCT COVERAGE

Active Vitamin D, Nutritional Vitamin D, Phosphate Binders, EPO agents, IV iron, Oral Iron

RELATED 2011 REPORTS

TreatmentTrends®: US Nephrology
TreatmentTrends®: Bone and Mineral (EU)
TreatmentTrends®: Renal Anemia (EU)
ChartTrends®: Bone and Mineral in Dialysis (US)
ChartTrends®: Bone and Mineral in CKD-ND(US)
ChartTrends®: Bone and Mineral (EU)
ChartTrends®: Renal Anemia in Dialysis (US)
ChartTrends®: Renal Anemia in CKD-ND (US)
ChartTrends®: Renal Anemia (EU)

PROJECT OBJECTIVES

- Understand the characteristics of CKD-ND (stage 3, 4, 5) and dialysis patients currently under the care of a nephrologist
 - Understand referral patterns, frequency of contact and follow up, laboratory tests and frequency of measurement
 - Patient co-morbidities, patient characteristics, and hospitalizations
 - Dialysis modality choices and vascular access
- Understand the treatment prevalence of bone and mineral metabolism and renal anemia agents in CKD and dialysis patients
 - Quantify the percent of patients in Stage 3, Stage 4, Stage 5 (not on dialysis), and Stage 5 (on dialysis) who are receiving bone and mineral metabolism therapies (calcimimetics, vitamin D, phosphate binders) and renal anemia therapies (EPO agents, IV iron, oral iron)
 - Understand the percent of patients who should be treated according to lab values and guidelines, but are not
 - Understand the differences between treated and non-treated patients
 - Understand the interplay between the various therapies. Are treated patients more likely to be treated across the board
 - Understand the triggers that prompt the use of therapies (i.e. co-morbidities, lab values)
- Understand bone and mineral metabolism and renal anemia treatment choices in CKD-ND and dialysis patients
 - What products are patients on and what factors drive product selection (i.e. co-morbidities, lab values, etc.)
 - Capture product dosing
- Identify gaps in intended vs. actual behavior by comparing self-reported survey responses with actual treatment records

DELIVERABLES

- Final report in powerpoint format
- Patient record database (in SPSS or Excel)

REPORT DATES

Date comments/proprietary questions are due	Field date	Publication date
May 1, 2011	May 15, 2011	August 25, 2011